Aura Biosciences, Inc. (NASDAQ:AURA) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants Announced: US$260.3M · US$6 a share · Leerink Partners +4 Dealers: Leerink Partners (co-lead), TD Cowen (co-lead), Evercore ISI (co-lead), LifeSci Capital, Citizens Capital Markets Use of proceeds: $205.1 million to advance clinical programs incl. early choroidal melanoma, bel-sar registration-enabling activities and general corporate purposes | May 4, 2026 |
| Public offering of equity Closed: US$75M raised · US$4.9 a share · Warrants at US$4.9 for 60 months · Leerink Partners +4 Dealers: Leerink Partners (co-lead), Evercore ISI (co-lead), LifeSci Capital, Citizens Capital Markets, Scotiabank Use of proceeds: Advance clinical programs in choroidal melanoma, choroid metastases, ocular surface cancers and bladder cancer, and general corporate purposes | Aug 13, 2025 |